ArKay Zero Proof Cuts Through Alcohol Culture -- And May Help Prevent Millions of Drunk Driving Incidents
With Global Alcohol Consumption Declining, ArKay Leads the Sober Revolution That's Saving Lives
MELBOURNE, Fla., May 19, 2025 /PRNewswire/ -- As alcohol consumption falls across the globe, one brand is emerging as a game-changing force in public health, personal choice, and road safety: ArKay Zero Proof. Available in over 35 countries and served in thousands of bars, lounges, restaurants, and hotel chains, ArKay is redefining the drinking experience — without alcohol and without compromise.
Arkay's Role in Preventing Drunk Driving
According to the World Health Organization, alcohol-related traffic accidents cause over 1.3 million injuries and deaths annually. ArKay offers a practical, scalable solution: zero-alcohol spirits that replicate the taste and complexity of traditional liquors — without the risk of intoxication.
In 2024, ArKay served an estimated 10 million bottles to:
Designated drivers
Pregnant women
Sober professionals
Health-conscious consumers
Each bottle served represents a potential drunk-driving incident averted.
"We don't just sell zero-proof spirits — we sell peace of mind," says Reynald Vito Grattagliano, founder of ArKay Beverages. "Every bottle of ArKay poured is a chance for someone to get home safe, stay sober, and still enjoy the moment."
Why People Are Drinking Less — And Choosing ArKay
This shift in behavior isn't accidental — it's cultural. Consumers are moving away from alcohol for deeply personal and global reasons, and ArKay is at the forefront of this transformation:
Health Awareness: Studies link alcohol to cancer, liver damage, depression, and poor sleep. ArKay offers enjoyment without the health risks.
Wellness Culture: Gen Z and Millennials are drinking 20% less than previous generations. ArKay caters to their values of mindfulness and balance.
Economic Realism: With alcohol prices rising, ArKay provides a cost-effective, tax-free alternative.
Sober Inclusion: ArKay breaks down social barriers for Muslims, people in recovery, and non-drinkers.
Professional Performance: Executives, creatives, and entrepreneurs are choosing clarity and mental sharpness over hangovers.
Powered by Beyond Spirits – The World's First Plant-Based Alcohol-Free Spirits Company
ArKay is now proudly part of Beyond Spirits, the global pioneer in plant-based, alcohol-free spirits. Using molecular technology and 100% natural ingredients, Beyond Spirits delivers the experience of drinking — without ethanol, toxicity, or compromise.
Consumers are embracing this innovation for:
Functional, plant-based ingredients
Total freedom from alcohol-related health risks
Halal and culturally inclusive options
A smarter, more sustainable lifestyle
From Melbourne to the World: A Billion-Dollar Brand with Global Reach
ArKay is already reshaping nightlife and sober living across the globe:
In Dubai, luxury hotels serve ArKay mocktails to elite guests observing health or religious restrictions.
In New York City, high-end lounges have reported a 38% increase in non-alcoholic cocktail sales — with ArKay's whiskey and gin leading the trend.
In Sweden, ArKay has partnered with event venues to create "Sober Zones" in cities with some of the strictest DUI laws in the world.
The Road Ahead: Sober-Driven and Globally Focused
ArKay is not just following a trend — it's shaping a movement. As governments tighten DUI laws and consumers demand safer, smarter alternatives, ArKay stands ready to expand into 50 countries by 2026, offering:
Scalable alcohol-free solutions
Luxury-grade alternatives for all lifestyles
Support for public safety and zero-tolerance initiatives
"We're not replacing alcohol — we're replacing regret," says Grattagliano.
About ArKay Beverages
Founded in 2011 in France, ArKay Beverages created the world's first alcohol-free spirit. Today, ArKay offers over 30 premium zero-proof options — from whiskey and vodka to tequila, amaretto, and rum — served in more than 35 countries.
Now part of Beyond Spirits, the world's first plant-based alcohol-free spirits company, ArKay is valued at $1.5 billion USD, thanks to its explosive global demand and visionary leadership in the zero-proof beverage space.
Media Contactpress@arkaybeverages.comwww.arkaybeverages.com+1 (956) 691-7252
View original content to download multimedia:https://www.prnewswire.com/news-releases/arkay-zero-proof-cuts-through-alcohol-culture--and-may-help-prevent-millions-of-drunk-driving-incidents-302458754.html
SOURCE BEYOND SPIRITS LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Honeywell International Inc. (HON): A Bull Case Theory
We came across a bullish thesis on Honeywell International Inc. (HON) on Business Model Mastery's Substack. In this article, we will summarize the bulls' thesis on HON. Honeywell International Inc. (HON)'s share was trading at $227.13 as of 9th June. HON's trailing and forward P/E were 26.11 and 22.22 respectively according to Yahoo Finance. Aerial shot of a bustling financial district, with imposing corporate buildings in the background. Honeywell represents one of the most deeply embedded and defensible industrial franchises in the global economy. Its business spans critical sectors like aviation, energy, buildings, and defense, but its strength lies in the quiet interconnection of its segments. In aviation, nearly half of the segment revenue, over $6.2 billion, is recurring, driven by aftermarket services such as predictive maintenance and avionics support, riding the global tailwind of increased flight hours. The UOP division, which licenses refining and chemical technologies, generates high-margin cash flows and long-term customer lock-in across thousands of global industrial sites. Honeywell Forge, the company's industrial cloud platform, overlays data intelligence on top of its hardware, offering sticky software solutions with 60 %+ margins that manage everything from aircraft maintenance to smart grid optimization. These embedded systems create a form of economic gravity—clients aren't bound by contracts, but by operational necessity. Geographically, Honeywell's 42% non-U.S. revenue and $3.44 billion in U.S. government contracts showcase both diversification and stability. Its scale, presence in 79 countries, and proprietary 'Honeywell Accelerator' performance system institutionalize excellence across 22,000+ internal tools, enhancing operational resilience. Competitive moats stem from product complexity, regulatory barriers, high switching costs, and vertically integrated offerings that span hardware, software, services, and materials. Even in challenged areas, such as warehouse automation, Honeywell improves margins through discipline. A $31.8 billion backlog further secures future earnings. Strategic acquisitions in 2023 reinforced cybersecurity, energy efficiency, and smart buildings. With a layered model built on systems, not headlines, Honeywell compounds quietly, by being indispensable infrastructure, not a fleeting trend. Previously, we highlighted a on Schlumberger from Business Model Mastery, which positioned the company as a digital-first oilfield services leader. With high-margin international growth, vertically integrated offerings, proprietary data, and strong client lock-in, SLB is viewed as a durable compounder amid energy's digital transformation. The stock price has appreciated by approximately 2% since the recent coverage. Honeywell International Inc. (HON) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 75 hedge fund portfolios held HON at the end of the first quarter which was 67 in the previous quarter. While we acknowledge the risk and potential of HON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Korn Ferry price target raised to $85 from $77 at Goldman Sachs
Goldman Sachs raised the firm's price target on Korn Ferry (KFY) to $85 from $77 and keeps a Buy rating on the shares after fiscal Q4 revenue, EBITDA margins and EPS came in ahead of the firm's estimates and consensus and guidance for Q1 exceeded Street expectations. The fourth edition of Talent Suite released in Q4 should drive accelerated digital segment revenue growth in calendar 2026 and potential upside to management's 16%-18% medium-term EBITDA margin target, the analyst tells investors. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on KFY: Disclaimer & DisclosureReport an Issue Korn Ferry's Resilience and Growth Potential Amid Economic Uncertainty Korn Ferry Reports Steady Growth Amidst Global Challenges Korn Ferry's Earnings Call: Strong Growth Amid Challenges Korn Ferry rises 13.1% Korn Ferry rises 16.5% Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
A longer ‘winter': Public funding slowdown heightens pressure on biotech startups
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology industry watchers were hopeful at the start of 2025. Venture funding appeared to be rebounding after a lengthy slump, and a smattering of new stock offerings and company acquisitions brewed optimism that the public markets might be similarly warming up to young drugmakers. But the positivity quickly dissipated. Trump administration policies gutted scientific research funding and raised questions about U.S. drug prices. Large layoffs and upheaval at public health agencies created regulatory turmoil that added risk to what's already, by its nature, a risky sector to invest in. The results were laid out in a June report from David Windley and Tucker Remmers, two analysts at the investment bank Jefferies. According to that report, funding in public biotech companies — be it from initial public offerings, follow-on stock offerings, or 'PIPE' deals — plummeted in May. The 'political and economic uncertainties' have "cast a cloud over biotech investment,' they wrote. 'Since product development cycles can range 12-15 years in this industry, biotechs (and their boards and investors) want clarity on FDA regulation, drug pricing, and funding before committing to large, [long-term] investments,' Windley and Remmers wrote. Investors and industry insiders interviewed by BioPharma Dive say that the public slowdown is trickling down to startups that have already been under intense pressure during a prolonged pullback. Companies and investors are struggling to align on valuations, making funding rounds more difficult to close than in prior years. The uphill battle in the public markets is further delaying IPO plans, too. "People are waiting to see what happens, and it's extended that winter," said Tim Scott, the president of Biocom California, an industry trade group. To date, only seven biotech companies have priced IPOs in 2025, and no large offerings have occurred since mid-February. No biotechs have publicly disclosed IPO ambitions in several months either, and one of the last to do so, Odyssey Therapeutics, pulled its offering in May. In a letter to the Securities and Exchange Commission, CEO Gary Glick wrote that it was 'not in the best interests of the company' to go public at that time. One reason IPOs have ground to a halt, experts say, is that the public markets aren't rewarding drug startups as predictably as they once were. Typically, drug companies can expect their value to climb after delivering positive clinical results. But 'even companies with good data aren't seeing a lot of movement in the public markets,' said Jonathan Norris, a managing director at HSBC Innovation Banking. As a result, Norris said, companies are looking at the time and expense it takes in the monthslong process to go public and wondering: 'What's the benefit?' 'If you have any readouts that are even eye squinting, you're going to get crushed,' he said. 'It's a tough, tough endeavor.' The shuttered IPO window is exacerbating problems for young biotechs. "If you don't have a public market opportunity, then the companies that are private have to think about ways to raise capital and stay private for longer," said Maina Bhaman, a partner at Sofinnova Partners. Feeling that burden, venture investors are becoming more conservative. While private funding hasn't plummeted as much as its public counterpart, investors are more selective and slower-moving. Funding has become increasingly consolidated into fewer and larger 'megarounds,' to the extent that more firms are compiling similar portfolios. And they're hard to finalize, even when most of a funding syndicate is already onboard, according to Norris. "People are struggling to figure out where the bottom of the market is and what's the appropriate valuation and expectation for that investment,' he said. "A lot of VCs are pencils down right now on deals they would otherwise be moving forward on,' Scott added. Pullbacks are nothing new in biotech. But what has been unusual, some say, is how long the sector has spent in the doldrums after peaking in early 2021. One reason is the most recent boom flooded the market with more companies than it could support. But another is that the ensuing correction has intensified amid regulatory and political upheaval. A report last week from Roel van den Akker, PwC's U.S. pharma and life science deals leader, predicted that companies will be 'preparing contingency plans' to account for delays in 'trial oversight' and drug applications. Drug companies are used to dealing with a high level of risk, as most experimental medicines never make it to market. But 'now you've got a lot more macro uncertainty that is being layered on top," Bhaman said. On the public side, that uncertainty has resulted in less patient investors, some of whom are pressing company boards to shut down after setbacks rather than change course. But some startups are taking drastic steps, too, such as cutting programs and staff to, some experts believe, depress their value so they can still attract investment. The "lack of surety" is pressuring biotechs to be as efficient as possible with their cash, Scott said, perhaps working on one program instead of a few. There have been multiple high-profile examples of late. Eikon Therapeutics and Insitro, two well-funded startups, both cited a need for 'prudence' in laying off staff. Norris expects more companies to proactively cut staff, or even close, as the longer-than-expected winter drags on. 'Most of those companies are not going to find the investors that they're hoping for,' he said. 'And I think that's just the unfortunate truth.' Recommended Reading Radiopharmaceutical drugmaker RayzeBio signals plans to go public
